SHELBY THOMAS: Open Payments
NPI 1295377877 · BRANDON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,820 in 91 payments from 20 companies in 2025. Trend: 2023 $1,803 · 2024 $1,784 · 2025 $1,820
Food & beverage: $1,820
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $389 |
| Lilly USA, LLC | 5 | $204 |
| Novo Nordisk Inc | 7 | $196 |
| Boston Scientific Corporation | 11 | $189 |
| PFIZER INC. | 9 | $175 |
| AstraZeneca Pharmaceuticals LP | 6 | $113 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $97 |
| Corcept Therapeutics | 4 | $82 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Astellas Pharma US Inc | 3 | $53 |
Products named: UBRELVY, Ozempic, General - Interventional Oncology, KISUNLA, VRAYLAR, NURTEC ODT, XIFAXAN, Korlym.
Industry payments across MS — which companies pay providers there.
